Navigation Links
Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis
Date:6/14/2008

oglobin

levels did not improve.

* Importantly, Soliris-treated PNH patients still experienced a moderate

improvement in fatigue (ES: +0.61) even when hemoglobin levels

decreased, while EPO-treated anemic cancer patients experienced a

small worsening of fatigue (ES:-0.33) when hemoglobin levels

decreased.

The improvement in fatigue associated with Soliris therapy in clinical trials was observed within the first week of treatment and has been sustained for more than two years. (10)

"As in cancer patients, fatigue in PNH patients is often severe enough to make the ordinary activities of daily life impossible," said Leonard Bell, M.D., Chief Executive Officer of Alexion. "This study indicates that patients can experience life-changing improvements in fatigue with long-term Soliris therapy regardless of changes in their anemia. This, and the other compelling clinical benefits that Soliris offers patients with PNH, are the basis for our commitment that every patient who can benefit from Soliris should have access to it."

About PNH

PNH is a rare blood disease that affects an estimated 8,000 to 10,000 people in North America and Europe and, using similar prevalence estimates, potentially 1,000 to 2,000 patients in Japan. (11) Although affecting all age groups, PNH often has an average age of onset in the early 30's. (12) Approximately 10 percent of all patients first develop symptoms at 21 years of age or younger. (4) PNH develops without warning and can occur in men and women of all races, backgrounds and ages. PNH often goes unrecognized, with delays in diagnosis often ranging from one to more than 10 years. (3) The estimated median survival for PNH patients is between 10 and 15 years from the time of diagnosis. (3,12)

PNH has been identified more commonly among patients with disorders of the bone marrow, including aplastic anemia (AA) and myelodysplastic syndrome (MDS). (13,14,15
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
2. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
3. PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
4. Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH
5. Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
6. Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
7. Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder
8. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
9. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
10. Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
11. New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... 13, 2014 Auf ... Tokio veranstalteten F&E-Tagung meldete Astellas ... Neuausrichtung seines Forschungsrahmenprogramms. Die Tagung bot Astellas ... fortgeschrittenen klinischen Programme und die Konzernstrategie des ... bestand darin, aktuelle Meldungen zu den Astellas-Initiativen ...
(Date:7/13/2014)... 2014  Eli Lilly and Company (NYSE: ... non-clinical study in genetically engineered mice examining combination ... antibody N3pG and beta-secretase inhibitor BACE (LY2811376). Data ... in removing clumps of amyloid-beta protein in the ... lead to Alzheimer,s disease (AD) – than use ...
(Date:7/11/2014)... ANGELES , July 11, 2014 /PRNewswire-iReach/ -- ... e-liquid, a vegetable-glycol solution for use in portable ... of the active ingredients in cannabis, cannabidiol offers ... personal vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds which ...
Breaking Medicine Technology:Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2
... Neurocrine Biosciences,Inc. (Nasdaq: NBIX ) today announced its financial ... quarter of 2008, the Company reported a,net loss of $21.1 ... of,$25.7 million, or $(0.68) per share, for the same period ... were $1.8 million compared with,$0.1 million for the same period ...
... April 30 CureDM, Inc., a,biopharmaceutical company developing ... 1 and 2 diabetes, announces its,achievement of a ... CureDM has successfully stabilized HIP to improve its,bioavailability ... used in man may be as much as ...
Cached Medicine Technology:Neurocrine Biosciences Reports First Quarter 2008 Results 2Neurocrine Biosciences Reports First Quarter 2008 Results 3Neurocrine Biosciences Reports First Quarter 2008 Results 4Neurocrine Biosciences Reports First Quarter 2008 Results 5Neurocrine Biosciences Reports First Quarter 2008 Results 6Neurocrine Biosciences Reports First Quarter 2008 Results 7Neurocrine Biosciences Reports First Quarter 2008 Results 8CureDM's Diabetes Therapy Achieves Major Development Milestone 2
(Date:7/13/2014)... Ticket Down is a reliable source for ... fifth straight year (and second under the current name), the ... this summer. The tournament features eight club teams from around ... split into two groups of four and upon the completion ... to become champion. One team that has had the most ...
(Date:7/13/2014)... 2014 Carolinas Healthcare System celebrated today ... Carolinas HealthCare System - Anson located in Anson County. ... Community Hospital in Wadesboro. , Located on U.S. Highway ... the previous facility. Situated on a 10-acre site, the ... emergency room drop-off, helipad, healing garden, and 15 beds. ...
(Date:7/13/2014)... Intraocular Lens (IOL) Market: Global Industry ... 2019 , Intraocular lens (IOL) is inserted in the ... The lenses are inserted inside the eye, after removal ... replaces the focusing power of natural lens. The pseudophakic ... deliver the light focusing function which was originally undertaken ...
(Date:7/13/2014)... Nature Genetics identifies a novel genetic and ... esophagitis (EoE), opening up potential new therapeutic strategies ... , EoE is a chronic inflammatory disorder of ... hypersensitivity to certain foods and an over-accumulation in ... (part of the body,s immune system). EoE can ...
(Date:7/13/2014)... for diagnosing type-1 diabetes could improve patient care ... according to the device,s inventors at the Stanford ... paper to be published online July 13 in ... to detect type-1 diabetes outside hospital settings. The ... of diabetes mellitus, which are both characterized by ...
Breaking Medicine News(10 mins):Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 3Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4
... EPIDEMIC ABROADMENLO PARK, Calif., May 7 Two-thirds of ... government funding to improve health in developing countries, while ... spending too much on global health, according to a ... towards U.S. global health and development assistance. Levels ...
... better than no treatment at all, study shows , , ... essential for reducing the risk of heart disease and ... matter of debate. , Now, two new analyses attempt ... attacks, all antihypertensive drugs work, with the exception of ...
... million adultsor one fourth of the people in the ... and this undiagnosed population accounts for an estimated $18 ... a study in a recent issue of Population ... Ann Liebert, Inc. ( www.liebertpub.com ). The article is ...
... of Illinois at Chicago has received nearly $1 million ... to study the benefits of green healthy housing. , ... and Reinvestment Act of 2009. , UIC researchers will ... move from distressed, unhealthy public housing into green, affordable, ...
... Results in New Compounded Medication Program GLEN BURNIE, ... largest practice-to-home delivery veterinary pharmacy today announced the ... than 1,200 pet owners from across the U.S.Key ... about having convenient services and options that help ...
... Pharma GmbH received an Orphan Drug Designation (ODD) by ... the EMEA for inhaled PARI Tobramycin 100 delivered via ... the second ODD designation that PARI Pharma has received ... first ODD was granted for PARI,s inhaled cyclosporine delivered ...
Cached Medicine News:Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 2Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 3Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 4Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 5Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 6Health News:All Blood Pressure Drugs Lower Risk of Heart Attack and Stroke 2Health News:All Blood Pressure Drugs Lower Risk of Heart Attack and Stroke 3Health News:UIC receives $1M HUD grant to study green healthy housing 2Health News:VetCentric Releases Findings of Pet Owner Survey 2Health News:PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward 2Health News:PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward 3Health News:PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward 4
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... Finnpipette Digital offers improved ergonomics for ... handle, modified grippy finger rest and ... comfort and efficiency. Finnpipette Digitals also ... gearing mechanism (pat. pend.) and super ...
Research Series 2100 Adjustable-volume Pipette,100-1,000 l, single-channel with adjustable-volume setting...
... The Sysmex pocH-100i is the first ... with low daily testing requirements. With its ... 3-part differential from just 15 L of ... for any small healthcare site including the ...
Medicine Products: